Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer

Radium-223 (Ra233) prolongs the survival of men with symptomatic bone-predominant metastatic castration-resistant prostate cancer (mCRPC). However, prostate-specific antigen (PSA) response patterns are not closely associated with Ra223 therapy outcomes. Herein, we sought to analyze the impact of Ra2...

Descripción completa

Detalles Bibliográficos
Autores principales: Sidhu, Amanjot, Khan, Nabeeha, Phillips, Cameron, Briones, Juan, Kapoor, Anil, Zalewski, Pawel, Fleshner, Neil E., Chow, Edward, Emmenegger, Urban
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488545/
https://www.ncbi.nlm.nih.gov/pubmed/37685670
http://dx.doi.org/10.3390/jcm12175604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488545/
https://www.ncbi.nlm.nih.gov/pubmed/37685670
http://dx.doi.org/10.3390/jcm12175604

Ejemplares similares